Strong Demand for Drug Components: West Pharma Expects Profits to Exceed Expectations in 2026
Feature: Focus on Q4 2025 US Stock Financial Reports
West Pharmaceutical announced on Thursday that, driven by strong demand for its patented products, the company’s fourth-quarter performance exceeded market expectations and it forecasts full-year profit in 2026 will surpass Wall Street estimates. The company’s products include syringes and cartridges for injectable drugs.
The shares of this Pennsylvania-based company rose 3.6% in pre-market trading.
The surging demand for new diabetes and obesity treatments, including Novo Nordisk's Ozempic, Wegovy, and Eli Lilly's Mounjaro, is expected to continue benefiting medical device manufacturers like West Pharmaceutical. The company provides core components for the injection pens of these drugs.
According to data from London Stock Exchange Group (LSEG), the company currently expects adjusted earnings per share for 2026 to be $7.85 to $8.20, higher than analysts’ forecast of $7.78.
Adjusted earnings per share for the first quarter are expected to be $1.65 to $1.70, with analysts expecting $1.65.
Full-year revenue is expected to be between $3.22 billion and $3.28 billion, compared with analysts’ average expectation of $3.25 billion.
West Pharmaceutical stated that the revenue forecast already includes income related to the sale of its SmartDose 3.5ml wearable injector system to AbbVie, a deal expected to be completed by mid-2026.
Meanwhile, the company’s fourth-quarter adjusted earnings per share were $2.04, exceeding the expected $1.83.
Quarterly total revenue was $805 million, higher than the expected $794.38 million.
The revenue of the patented products division, which accounts for more than half of the company's total revenue, reached $661.8 million, exceeding the expected $652.95 million.
The contract manufactured products division's quarterly sales increased by 6.2% year-on-year to $143.2 million, slightly below the expected $143.3 million. This division benefited from rising demand for self-injection devices for obesity and diabetes, though a decline in sales of medical diagnostic devices partially offset this growth.
Editor: Guo Mingyu
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
High U.S. Treasury yields exert pressure, bank stock index deeply in correction zone, Citigroup drops nearly 5% intraday
During Thursday's trading, the KBW Bank Index hit a four-month low, falling 14% from its mid-August peak. Analysts noted that in September, the financial sector's performance relative to other industries was the worst for the same period since 1990. Some analysts also pointed out that concerns over the threat of AI agents, potential impacts from the US midterm elections, and rising interest rates have been overblown. The major banks' earnings season begins on October 13, with profitability becoming a key point of validation.
XRP ETF Demand Rises as Institutional Inflows Grow
Nasdaq Futures Long Positioning Hits 50% of Open Interest — Highest Since 2017
JPMorgan: Risks in the U.S. Stock Market—Leverage Is Back
Crypto prices
More
